TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34930299

Group type: EXPERIMENTAL
Intervention: Change in number of steps
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Dietary factors (less alcohol, fatty and sugary food, more fruit and vegetables)
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Fatty food score
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Sugary food score
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Change in weight
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Baseline values and change in weight
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Change in body weight
Number of subjects: 707
Study: 33678716

Group type: EXPERIMENTAL
Intervention: Configurational priming in DHH participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonological priming in DHH participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hearing participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHH participants
Number of subjects: 0
Study: 32277872

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum HI-MIMBb75 (1×10^9 non-viable cells, taken orally once a day for 8 weeks)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo (two capsules taken orally once a day for 8 weeks)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum HI-MIMBb75
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 35236137

Group type: EXPERIMENTAL
Intervention: Prompting
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Breaks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sensory proprioception
Number of subjects: 15
Study: 34615893

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 56
Study: 32286644

Group type: EXPERIMENTAL
Intervention: Preemptive therapy (valganciclovir, 900 mg, twice daily until 2 consecutive negative tests a week apart for 100 days)
Number of subjects: 205
Study: 35354778

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Condition-specific quality of life measures
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 166
Study: 33549516

Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the left dorsolateral prefrontal cortex
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the right dorsolateral prefrontal cortex
Number of subjects: 40
Study: 32877155

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional osteotomy
Number of subjects: 72
Study: 33814199

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 34266308

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Control (no EVT)
Number of subjects: 1242
Study: 32246655

Group type: EXPERIMENTAL
Intervention: Glass ionomer restorative system (Equia™)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bulk-fill composite (Sonicfill™)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bulk-fill composite (X‐tra fil™)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nanohybrid composite (Filtek Z550™)
Number of subjects: 30
Study: 33440447

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a‐tDCS) over the primary motor cortex (M1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 24
Study: 616084013

Group type: EXPERIMENTAL
Intervention: Argon Laser Peripheral Iridoplasty (ALPI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 22
Study: 35276031

Group type: EXPERIMENTAL
Intervention: bMBI (Brief Mindfulness-Based Intervention)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 63
Study: 33243246

Group type: COMPARATOR
Intervention: Physically Active Learning (PAL) intervention: 30 min physically active learning, 30 min PA, and a 60 min physical education (PE) lesson per week.
Number of subjects: 2084

Group type: COMPARATOR
Intervention: Don't worry-Be happy (DWBH) intervention: 60 min PA lesson and a 60 min PE lesson per week, tailored to promote friendships and wellbeing.
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Control group: standard amount of mandatory PE lessons without additional interventions.
Number of subjects: 2084
Study: 34896870

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Social Skills Training (CBSST)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Treatment‐As‐Usual (TAU)
Number of subjects: 63
Study: 34984065

Group type: EXPERIMENTAL
Intervention: Supportive care plus colchicine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Supportive care plus budesonide inhaler
Number of subjects: 49

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 49
Study: 32426316

Group type: EXPERIMENTAL
Intervention: Group nutrition counseling (GNC)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Individualized nutrition prescription (INP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study: 35838438

Group type: COMPARATOR
Intervention: Ketamine treatment in clinical trials (exact dosage and duration not specified)
Number of subjects: 380
Study: 34914258

Group type: EXPERIMENTAL
Intervention: Compound Chamomile and Lidocaine Hydrochloride Gel
Number of subjects: 116

Group type: COMPARATOR
Intervention: Primary Snodgrass urethroplasty only
Number of subjects: 116
Study: 33714700

Group type: EXPERIMENTAL
Intervention: TPR technique (skin traction, pressure, rapid muscle release)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Z‐track injection method
Number of subjects: 63
Study: 34738912

Group type: EXPERIMENTAL
Intervention: Digital self-management program (HOPE)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 61
Study: 32145441

Group type: EXPERIMENTAL
Intervention: LEAPS intervention (lay health worker support)
Number of subjects: 0
Study: 33831770

Group type: EXPERIMENTAL
Intervention: Add-on yoga treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Treatment as usual (TAU - wait-list control)
Number of subjects: 89
Study: 36107614

Group type: EXPERIMENTAL
Intervention: Esmolol (1.0 mg/kg bolus before intubation, continuous infusion during surgery, and 1.0 mg/kg bolus after surgery)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Esmolol (1.0 mg/kg bolus before intubation, continuous infusion during surgery, and 1.0 mg/kg bolus after surgery) + Ramosetron (0.3 mg after surgery)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ramosetron (0.3 mg after surgery)
Number of subjects: 165
Study: 33630618

Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 219
Study: 32451528

Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy (EAET)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 53
Study: 36267757

Group type: EXPERIMENTAL
Intervention: Individualized pharmaceutical care
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 118
Study: 33443770

Group type: EXPERIMENTAL
Intervention: Provocation condition
Number of subjects: 231

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 231
Study: 35311346

Group type: EXPERIMENTAL
Intervention: Salt substitute
Number of subjects: 20995
Study: 33484336

Group type: EXPERIMENTAL
Intervention: Distal cuff inflation to 60 mmHg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Proximal cuff inflation to 60 mmHg
Number of subjects: 25

Group type: COMPARATOR
Intervention: No cuff inflation (Control)
Number of subjects: 25
Study: 32556539

Group type: EXPERIMENTAL
Intervention: Imeglimin 2250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imeglimin 6000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34240819

Group type: EXPERIMENTAL
Intervention: Low-dose aerobic exercise (150 min/week)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: High-dose aerobic exercise (300 min/week)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (<75 min/week)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (for overweight women)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (for normal weight women)
Number of subjects: 139
Study: 33573133

Group type: EXPERIMENTAL
Intervention: H2‐rich calcium powder (HCP) (1500 mg/day, containing 2.544 µg/day of H2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: H2‐depleted placebo (1500 mg/day)
Number of subjects: 18
Study: 35358965

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) + Melatonin (MLT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle (sterile saline)
Number of subjects: 30
Study: 34758017

Group type: EXPERIMENTAL
Intervention: 2-dose ivermectin-based MDA (IVM-2)
Number of subjects: 3812

Group type: EXPERIMENTAL
Intervention: 1-dose ivermectin-based MDA (IVM-1)
Number of subjects: 3812

Group type: EXPERIMENTAL
Intervention: Screen and treat with topical permethrin 5% (SAT)
Number of subjects: 3812
Study: 32556960

Group type: EXPERIMENTAL
Intervention: Corticosteroids for 3 days
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 546
Study: 35475533

Group type: EXPERIMENTAL
Intervention: PRagmatic Explanatory Continuum Indicator Summary 2 (PRECIS‐2) tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized study design types (parallel, crossover, factorial, stepped‐wedge)
Number of subjects: 0
Study: 34781955

Group type: EXPERIMENTAL
Intervention: A‐PRF+ (test, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: EMD (control, n = 15)
Number of subjects: 30
Study: 33681741

Group type: EXPERIMENTAL
Intervention: Long-term mild hypothermia (34–35 °C for 5 days)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Normothermia (37 °C)
Number of subjects: 302
Study: 32063399

Group type: EXPERIMENTAL
Intervention: Single-arm studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Externally controlled trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: External control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Externally controlled studies
Number of subjects: 0
Study: 33574421

Group type: COMPARATOR
Intervention: Control infant formula
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Investigational infant formulas with 0.8 g/100 ml scGOS/lcFOS and Bifidobacterium breve M‐16V at either 1 × 104 cfu/ml or 1 × 106 cfu/ml
Number of subjects: 290
Study: 32232776

Group type: EXPERIMENTAL
Intervention: JuniorLEAP group therapy programme
Number of subjects: 32
Study: 35862897

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (psychoeducation)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (computer)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (therapist-directed)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (integrated)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (all treatment arms)
Number of subjects: 69
Study: 34659680

Group type: EXPERIMENTAL
Intervention: HBM education
Number of subjects: 268
Study: 33447003

Group type: EXPERIMENTAL
Intervention: AEON™ Endostapler
Number of subjects: 60

Group type: COMPARATOR
Intervention: Echelon Flex™ Powered Stapler
Number of subjects: 60
Study: 35066944

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Radio-frequency (RF) ablation using ablation index (AI) following the CLOSE protocol
Number of subjects: 150
Study: 34688088

Group type: EXPERIMENTAL
Intervention: Planned delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study: 33094666

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32692124

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) intervention involving weekly individual sessions with a therapist and practice of computerized CR exercises between sessions.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) intervention
Number of subjects: 20
Study: 33742060

Group type: EXPERIMENTAL
Intervention: Molecular hydrogen (H2) supplement
Number of subjects: 10
Study: 36316077

Group type: EXPERIMENTAL
Intervention: Online individualised therapy group (ITG) receiving professional advice on LBP and musculoskeletal problems via online interview and email for 6 months.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual group (UG) with access to brochures and video feeds related to LBP and fall prevention.
Number of subjects: 120
Study: 32746799

Group type: EXPERIMENTAL
Intervention: Patient activation and education (PAE) including text messaging and print materials
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Patient activation and education (PAE) plus primary care physician activation (PAE + Phys)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Patient activation and education (PAE) plus primary care physician activation (PAE + Phys) plus teledermoscopy (PAE + Phys + TD)
Number of subjects: 720
Study: 35278462

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to the right cerebellum
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 36
Study: 32469166

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (22 subjects)
Number of subjects: 30
Study: 33781238

Group type: EXPERIMENTAL
Intervention: Combined exercise (CE: quadriceps strengthening exercises (QSE) and Baduanjin qigong training (BDJ))
Number of subjects: 128

Group type: COMPARATOR
Intervention: Quadriceps strengthening exercises (QSE)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Baduanjin qigong training (BDJ)
Number of subjects: 128
Study: 34225091

Group type: EXPERIMENTAL
Intervention: 12-month exercise trial after adjuvant treatment
Number of subjects: 342

Group type: COMPARATOR
Intervention: Age-matched general female population (n = 892)
Number of subjects: 342
Study: 34125440

Group type: EXPERIMENTAL
Intervention: Immediate endoscopic dacryocystorhinostomy (En-DCR)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Delayed endoscopic dacryocystorhinostomy (En-DCR) after 2 to 5 days of antibiotic treatment
Number of subjects: 160
Study: 33904998

Group type: EXPERIMENTAL
Intervention: Mesh tail crossing (group C)
Number of subjects: 116

Group type: COMPARATOR
Intervention: No mesh tail crossing (group N)
Number of subjects: 116
Study: 36096863

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 44
Study: 32009442

Group type: EXPERIMENTAL
Intervention: Individual computer magnanimous therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group computer magnanimous therapy
Number of subjects: 0
Study: 32327474

Group type: EXPERIMENTAL
Intervention: Pharmacist assessment every 8 weeks for 12 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pharmacist assessment
Number of subjects: 39
Study: 34902530

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 501

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 501
Study: 34845428

Group type: EXPERIMENTAL
Intervention: ABMDC (Autologous Bone Marrow-Derived Chondrocytes), single injection of 5 million
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (treatment they were taking)
Number of subjects: 60
Study: 33190160

Group type: EXPERIMENTAL
Intervention: Meal at night (N=12; 7 males)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Snack at night (N=13; 7 males)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No eating at night (N=14; 9 males)
Number of subjects: 39
Study: 32271318

Group type: EXPERIMENTAL
Intervention: Sedated reduction
Number of subjects: 319

Group type: COMPARATOR
Intervention: Nonsedated immobilization
Number of subjects: 319
Study: 33184667

Group type: EXPERIMENTAL
Intervention: Peer-led weight loss intervention (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual WIC care (n = 11)
Number of subjects: 22
Study: 32308128

Group type: EXPERIMENTAL
Intervention: SEC‐coated circuit (SEC group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin‐coated circuit (control group)
Number of subjects: 20
Study: 36253971

Group type: EXPERIMENTAL
Intervention: TAP block with 40 mL of 0.375% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with 40 mL of normal saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 34371382

Group type: EXPERIMENTAL
Intervention: Xpert Breast Cancer STRAT4 (RT-qPCR detection of mRNA)
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Central IHC (and ISH for HER2 IHC 2+)
Number of subjects: 1115
Study: 32905675

Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac (750 mg eflornithine, 150 mg sulindac, both once daily for up to 48 months)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Sulindac (150 mg once daily for up to 48 months)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Eflornithine (750 mg once daily for up to 48 months)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac vs Sulindac
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac vs Eflornithine
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac in precolectomy patients
Number of subjects: 171

Group type: COMPARATOR
Intervention: Sulindac in precolectomy patients
Number of subjects: 171

Group type: COMPARATOR
Intervention: Eflornithine in precolectomy patients
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac in rectal or ileal pouch polyposis patients
Number of subjects: 171

Group type: COMPARATOR
Intervention: Sulindac in rectal or ileal pouch polyposis patients
Number of subjects: 171

Group type: COMPARATOR
Intervention: Eflornithine in rectal or ileal pouch polyposis patients
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Eflornithine plus Sulindac in duodenal polyposis patients
Number of subjects: 171

Group type: COMPARATOR
Intervention: Sulindac in duodenal polyposis patients
Number of subjects: 171

Group type: COMPARATOR
Intervention: Eflornithine in duodenal polyposis patients
Number of subjects: 171
Study: 35980649

Group type: EXPERIMENTAL
Intervention: Etoposide plus cisplatin (EP) - etoposide (100 mg/m2/d on days 1, 2, and 3) and cisplatin (80 mg/m2/d on day 1) every 3 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Irinotecan plus cisplatin (IP) - irinotecan (60 mg/m2/d on days 1, 8, and 15) and cisplatin (60 mg/m2/d on day 1) every 4 weeks
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Irinotecan plus cisplatin (IP)
Number of subjects: 170
Study: 33600205

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (offline) to the prefrontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (offline) to the superior medial frontal cortex (SMFC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulation targeting the SMFC
Number of subjects: 0
Study: 32349711

Group type: EXPERIMENTAL
Intervention: Ligation of the dorsal branch of the cephalic vein
Number of subjects: 115

Group type: COMPARATOR
Intervention: No ligation of the dorsal branch of the cephalic vein
Number of subjects: 115
Study: 36088297

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB) + intercostal nerve block (ICNB)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) + intercostal nerve block (ICNB)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Intercostal nerve block (ICNB)
Number of subjects: 173
Study: 33164569

Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 448

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 448
Study: 33944585

Group type: EXPERIMENTAL
Intervention: Interval training (5 sessions over 3 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bulk training (2 sessions within 3 days)
Number of subjects: 17
Study: 34582715

Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg twice daily plus add-back therapy (E2 1 mg/NETA 0.5 mg once daily)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Elagolix with add-back therapy
Number of subjects: 367
Study: 32365403

Group type: EXPERIMENTAL
Intervention: Minimally processed vegetables
Number of subjects: 100
Study: 34750975

Group type: EXPERIMENTAL
Intervention: Facebook‐based intervention (FIIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 60
Study: 33051814

Group type: EXPERIMENTAL
Intervention: Buccal infiltration anesthesia (1.5 ml of 2% lidocaine with 1:80,000 epinephrine)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Buccal and lingual infiltration anesthesia (1.5 ml of 2% lidocaine with 1:80,000 epinephrine by buccal injection and 0.3 ml of the same solution injected into the lingual side)
Number of subjects: 66
Study: 36346210

Group type: EXPERIMENTAL
Intervention: High dose isotretinoin (0.6 mg/kg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low dose isotretinoin (0.3 mg/kg/day)
Number of subjects: 100